The U.S. Food and Drug Administration has granted final approval to Sun Pharmaceutical Industries' abbreviated new drug application for imatinib mesylate tablets in a paediatric-optimised dosage form, therapeutically equivalent to Novartis's Gleevec, according to regulatory records published Sunday. The approval covers the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia in paediatric patients, a population for which access to affordable tyrosine kinase inhibitors has historically been constrained by originator pricing.

Sun Pharma, headquartered in Mumbai and one of the largest generic pharmaceutical manufacturers by global revenue, confirmed the ANDA clearance through a filing to Indian exchanges Sunday morning. The company's shares rose in early trading on the BSE, continuing a pattern seen with recent Indian generic approvals in oncology. Analysts at ICICI Securities noted the approval consolidates Sun Pharma's growing paediatric oncology generic portfolio in the United States, its single largest market by revenue.

The approval arrives as May is designated Brain Tumour and Cancer Awareness Month across several healthcare systems, intensifying public and institutional focus on the cost burden of oncology therapies. Patient advocacy groups, including the Leukaemia and Lymphoma Society, have previously flagged that paediatric patients face disproportionate access barriers when branded oncology drugs retain market exclusivity or when generic entrants are slow to reach pharmacy shelves.

Novartis's Gleevec, which transformed CML treatment following its landmark FDA approval in 2001, has faced generic competition in the adult formulation market for several years, but paediatric-specific generics have been slower to emerge due to complex formulation requirements and smaller commercial incentives. Sun Pharma's entry is expected to prompt price reductions of between 30 and 50 percent at the wholesale level for paediatric CML treatment programmes run by children's hospitals and oncology centres across the United States.

The approval is the latest in a string of oncology generic clearances by Indian manufacturers in 2026, following recent Health Canada and FDA actions on bevacizumab biosimilars and semaglutide generics. Industry observers say the cadence of approvals reflects both a maturing FDA review pipeline post-pandemic and intensifying competition among Indian generics manufacturers for a share of the high-value oncology market. Sun Pharma is expected to begin shipping the product to major US wholesalers including McKesson and AmerisourceBergen within the coming weeks.